Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-09-30 pm EDT
163.36 USD   -0.71%
09/28Trending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09/28Johnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
PU
09/28Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson's Q2 Headwinds Pull Back Optimism on FY2022 Performance, D.A. Davidson Says

08/03/2022 | 03:43pm EDT


© MT Newswires 2022
All news about JOHNSON & JOHNSON
09/28Trending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09/28Johnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the L..
PU
09/28Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
09/28Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
BU
09/28Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
CI
09/27Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults wi..
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash 2022 9 791 M - -
P/E ratio 2022 20,0x
Yield 2022 2,68%
Capitalization 430 B 430 B -
EV / Sales 2022 4,39x
EV / Sales 2023 4,11x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 163,36 $
Average target price 185,07 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296
NOVO NORDISK A/S3.59%227 057